Industry News

- Read more about Ferring Pharma's new room temperature stable formulation of Pabal approved through EU
Ferring Pharmaceuticals, a research-driven, specialty biopharmaceutical group active in global markets, announced that EU has approved its new room-temperature-stable formulation of Pabal (carbetocin) for intravenous (IV) administration.
- Read more about Novo Nordisk opens modern insulin formulation and filling facility in Russia
Novo Nordisk opens a new manufacturing facility in Russia for formulation and filling of modern insulin for the treatment of diabetes. The production will cover both Penfill® cartridges and FlexPen® prefilled insulin injection pens for the Russian market.
- Read more about Biocon Strengthens its Presence in Mexico, Receives Approval for Insulin Glargine through its Partner PiSA Farmaceutica
Biocon Ltd, Asia's premier biopharmaceuticals company, announced that its Insulin Glargine has been approved by COFEPRIS, the Mexican health authority, through its partner PiSA Farmaceutica (PiSA).
- Read more about Daiichi Sankyo's “Savaysa” got approval from FDA
The U.S. Food and Drug Administration granted approval to Savaysa (edoxaban tablets) as anticlotting drug. This drug is used to reduce dangerous blood clots in patients with atrial fibrillation, deep vein thrombosis and pulmonary embolism.
- Read more about Novocure's Optune: A big hope for patients with recurrent glioblastoma
Glioblastomas (GBM) are tumors that arise from astrocytes—the star-shaped cells that make up the “glue-like,” or supportive tissue of the brain. These tumors are usually highly malignant (cancerous) because the cells reproduce quickly and they are supported by a large network of blood vessels Approximately 10,000 patients diagnosed each year in the US and approximately 1,600 patients diagnosed each year in Japan.
- Read more about Abbott’s strengthens India by introducing Flash Glucose Monitoring system for diabetics
Diabetes is fast gaining the status of a potential epidemic in India with more than 62 million diabetic individuals currently diagnosed with the disease.India now carries 20 per cent of the global burden of diabetes.
- Read more about Dr. Reddy’s Laboratories to acquire select portfolio of UCB in India
Dr. Reddy’s Laboratories announced that it has entered into a definitive agreement to acquire a select portfolio of the established products business of UCB, in the territories of India, Nepal, Sri Lanka and Maldives. The acquired business is being sold on a slump sale basis. The transaction includes approximately 350 employees engaged in operations of the India Business. The revenues of the acquired business is approximately INR 150 Crores for calendar year 2014.

[adsense:336x280:8701650588]
- Read more about PAREXEL announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services-
PAREXEL International Corporation, a global clinical research organization, announced today that the Company has signed a definitive agreement to acquire all of the business assets of privately-owned Quantum Solutions India (QSI), a leading provider of specialized pharmacovigilance services, based in Chandigarh, India. Pharmacovigilance refers to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. The acquisition is expected to close in early April of 2015, subject to the satisfaction of closing conditions.
- Read more about Novo Nordisk to launch Novoeight® in the United States for People With Hemophilia A
Novo Nordisk today announced the company will launch Novoeight^®(Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A. Novoeight^® offers purity, reliability, and enhanced portability, with the highest storage temperature for the longest period of time compared with other marketed recombinant Factor VIII products—up to 86 degrees F for 12 months. It can be kept at that temperature for up to 4 hours after reconstitution, giving it the longest postreconstitution storage time. Novoeight^® offers purity through a 5-step purification process. It was shown to be safe and effective in clinical trials with zero inhibitors confirmed in 213 previously treated patients with hemophilia A. Novo Nordisk plans to make Novoeight^® available by mid-April 2015.
- Read more about Tumor Ablation Market Worth $462.0 Million by 2019
According to a new market research report "Tumor Ablation Market by Procedure Volume, Technology (RF, Microwave, Cryoablation, Others), Department (Interventional Radiology, Surgery, Oncology), Application (Liver Cancer, Lung Cancer, Kidney Cancer, Bone Metastasis) - Global Forecasts to 2019", published by MarketsandMarkets, the Tumor Ablation Market is expected to reach around $462.0 Million growing at a CAGR of 11.50% by 2019.